Angiopoietin-like 3 monomers are abundant in human plasma but are unable to inhibit endothelial lipase
JCI Insight · 2025
DOI: 10.1172/jci.insight.197827 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2025. Verfasst von Sydney G Walker und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Fraternal Order of Eagles Diabetes Research Center, and Obesity Research and Education Initiative, …. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 3, Lipase, Angiopoietin-like Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health, American Heart Association.
Abstract (Originalsprache)
Angiopoietin-like 3 (ANGPTL3) is a major regulator of lipoprotein metabolism. ANGPTL3 deficiency results in lower levels of triglycerides, LDL-cholesterol (LDL-C), and HDL-cholesterol (HDL-C), and may protect from cardiovascular disease. ANGPTL3 oligomerizes with ANGPTL8 to inhibit lipoprotein lipase (LPL), the enzyme responsible for plasma triglyceride hydrolysis. Independently of ANGPTL8, oligomers of ANGPTL3 can inhibit endothelial lipase (EL), which regulates circulating HDL-C and LDL-C levels through the hydrolysis of lipoprotein phospholipids. The N-terminal region of ANGPTL3 is necessary for both oligomerization and lipase inhibition. However, our understanding of the specific residues that contribute to these functions is incomplete. In this study, we performed mutagenesis of the N-terminal region to identify residues important for EL inhibition and oligomerization. We also assessed the presence of different ANGPTL3 species in human plasma. We identified a motif important for lipase inhibition, and protein structure prediction suggested that this region interacted directly with EL. We also found that recombinant ANGPTL3 formed a homotrimer and was unable to inhibit EL activity when trimerization was disrupted. Surprisingly, we observed that human plasma contained more monomeric ANGPTL3 than trimeric ANGPTL3. An important implication of these findings is that previous correlations between circulating ANGPTL3 and circulating triglyceride-rich lipoproteins need to be revisited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Fraternal Order of Eagles Diabetes Research Center, and Obesity Research and Education Initiative, University of Iowa, Iowa City, Iowa, USA.
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
- Department of Chemistry, Waldorf University, Forest City, Iowa, USA.
- Finsen Laboratory, Copenhagen University Hospital-Rigshospitalet, Copenhagen N, Denmark.
- Finsen Laboratory, Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen N, Denmark.
Förderung
- NHLBI NIH HHS
- National Institutes of Health
- American Heart Association
Zitieren
APA
Walker, S. G., Chen, Y. Q., Sylvers-Davie, K. L., Dou, A., Zhen, E. Y., Qian, Y., Wen, Y., Ehsani, M., Smith, S., Thapa, R., Mercer, M. J., Langmack, L., Bhattarai, B. R., Ploug, M., Konrad, R. J., & Davies, B. S. (2025). Angiopoietin-like 3 monomers are abundant in human plasma but are unable to inhibit endothelial lipase. JCI Insight. https://doi.org/10.1172/jci.insight.197827
Vancouver
Walker SG, Chen YQ, Sylvers-Davie KL, Dou A, Zhen EY, Qian Y, et al. Angiopoietin-like 3 monomers are abundant in human plasma but are unable to inhibit endothelial lipase. JCI Insight. 2025. doi:10.1172/jci.insight.197827
BibTeX
@article{Walker2025,
author = {Walker, Sydney G and Chen, Yan Q and Sylvers-Davie, Kelli L and Dou, Alex and Zhen, Eugene Y and Qian, Yuewei and Wen, Yi and Ehsani, Mariam and Smith, Sydney and Thapa, Rakshya and Mercer, Maxwell J and Langmack, Lucy and Bhattarai, Bharat Raj and Ploug, Michael and Konrad, Robert J and Davies, Brandon Sj},
title = {Angiopoietin-like 3 monomers are abundant in human plasma but are unable to inhibit endothelial lipase},
journal = {JCI Insight},
year = {2025},
doi = {10.1172/jci.insight.197827}
}
EUVIMED